Accelerate Diagnostics makes rapid diagnostic systems for hospital microbiology labs that test blood samples for bacterial infections and antibiotic susceptibility. The core problem Accelerate targets is that traditional diagnostic methods take 2-3 days to identify a pathogen and determine effective antibiotics — a critical delay for sepsis patients where early antibiotic optimization is essential. Accelerate's flagship product, the Accelerate Pheno system, compresses that timeline to roughly 7 hours using a two-step process: fluorescent in situ hybridization (FISH) to identify the pathogen, followed by live-cell imaging to determine antibiotic susceptibility. Accelerate also sells the Accelerate Arc system, which automates sample preparation for MALDI-TOF mass spectrometry identification, enabling results in 1-2 hours versus overnight with traditional methods. Accelerate uses a razor/razor-blade model — instruments are placed at hospitals, and recurring revenue comes from single-use consumable test kits per patient sample. BD serves as the exclusive worldwide sales agent for both products under a partnership arrangement in place since 2022. Accelerate's next-generation platform, WAVE, is currently in clinical trials, with an FDA submission targeted for early 2025. WAVE uses digital holographic microscopy to deliver AST results in roughly 4.5 hours and can handle both blood culture and isolated colony samples on a single instrument — expanding Accelerate's addressable market beyond its current blood culture focus. Management's key near-term priorities are obtaining FDA clearance for WAVE, converting the existing Pheno installed base to WAVE, and securing a global commercial partner for the new platform.